| Deal value | $450M |
|---|---|
| Share of market cap | 15.6% |
Key highlights
- Issued 6,000,000 common shares at a fixed price of $75.00 per share
- Underwriters granted a 30-day option for an additional 900,000 shares
- Net proceeds estimated at $422.4 million after standard transaction costs
- Projected cash runway extended to 2030 for operations and debt service
- Preliminary Q3 2026 cash and equivalents reported at $682.8 million
What Is the Capital Raise?
Disc Medicine completed an upsized underwritten public offering of 6,000,000 common shares priced at $75.00 each, generating $450 million in gross proceeds. The offering officially closed on October 22, 2026, with Jefferies, Leerink Partners, Morgan Stanley, and Cantor acting as joint book-running managers. Beyond the primary issuance, the company granted underwriters a 30-day option to acquire an additional 900,000 shares at the same public offering price. This transaction significantly strengthens the balance sheet, following a preliminary cash report of $682.8 million as of September 30, 2026, ensuring high liquidity for upcoming clinical programs.
Use of Proceeds
- Funding research and clinical development of the current hematology pipeline
- Supporting the potential commercialization of bitopertin for EPP and XLP
- Advancing pre-commercialization activities for additional product candidates
- Financing debt service obligations and general working capital requirements
Strategic Rationale
The timing of this capital raise aligns with critical regulatory milestones, including the targeted resubmission of the New Drug Application for bitopertin by year-end 2026. By securing this capital now, Disc Medicine extends its operational runway into 2030, effectively de-risking the financial path through potential FDA approval and market launch. This long-term funding strategy reduces the immediate need for dilutive financing during the mid-stage commercialization phase. The extension into the next decade ensures that the company can maintain momentum across its broader portfolio without relying on immediate cash inflows from marketed products.
Business Overview
Based in Watertown, Massachusetts, Disc Medicine is a clinical-stage biopharmaceutical firm focused on the discovery and commercialization of treatments for serious hematologic diseases. Its primary focus involves targeting fundamental biological pathways, such as heme synthesis and iron metabolism. The flagship candidate, bitopertin, is being developed for erythropoietic protoporphyria, a rare condition characterized by intense photosensitivity. The company's pipeline also includes programs aimed at addressing other erythroid and iron-related disorders, leveraging a diverse set of therapeutic mechanisms to address significant unmet needs in the global hematology sector.
Financial Context
Disc Medicine has maintained an active financing profile, including a 250 million dollar offering in October 2025 and a 225.5 million dollar raise in January 2025. This latest 450 million dollar transaction marks a significant step up in scale, nearly doubling the size of previous rounds. Prior to this offering, the company reported 718 million dollars in cash and equivalents as of June 30, 2026, with a runway that previously extended into 2029. The inclusion of these new proceeds, alongside existing credit facilities, provides one of the most substantial cash cushions among clinical-stage biotechnology peers.
Up 2.1% since our story on 22 Oct: $75.03 when we broke it → $76.59 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $78.93 |
|---|---|
| 20 Oct | $79.48 |
| 21 Oct | $76.00 |
| 22 Oct | $75.03 |
| 23 Oct | $74.51 |
| 26 Oct | $77.66 |
| 27 Oct | $79.90 |
| 28 Oct | $83.20 |
| 29 Oct | $82.84 |
| 30 Oct | $80.84 |
| 2 Nov | $78.62 |
| 3 Nov | $81.16 |
| 4 Nov | $83.28 |
| 5 Nov | $78.47 |
| 6 Nov | $78.91 |
| 9 Nov | $81.26 |
| 10 Nov | $84.64 |
| 11 Nov | $87.08 |
| 12 Nov | $83.23 |
| 13 Nov | $80.00 |
| 16 Nov | $76.59 |
| Date | Announcement | Amount |
|---|---|---|
| 20 Oct 2026 | Pricing of upsized public offering of common stockSource: ir.discmedicine.com | $450.0 Million |
| 25 Jun 2026 | First amendment to loan agreement and term loan drawdownSource: SEC filing | $30.0 Million |
| 21 Oct 2025 | Pricing of upsized public offering of common stock and pre-funded warrantsSource: ir.discmedicine.com | $250.0 Million |
| 22 Jan 2025 | Pricing of upsized public offering of common stock and pre-funded warrantsSource: ir.discmedicine.com | $225.5 Million |
| 15 Nov 2024 | Controlled equity offering sales agreement (at-the-market equity offering program)Source: ir.discmedicine.com | $200.0 Million |
| 06 Nov 2024 | Loan and security agreement for senior secured term loan facilitySource: ir.discmedicine.com | $200.0 Million |
| Share price | $75.03 |
|---|---|
| Market cap | $2.9B |
| 1-month price change | +9.56% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Disc Medicine, Inc. announcing the closing of a $450 million underwritten public offering.
Track Disc Medicine, Inc. live
Get the next Disc Medicine, Inc. SEC filing seconds after it lands.




